Scholars Central

Conference abstractPublished 14 Sep 2015

Pump therapy in Type 2 Diabetes: Novel approach to Glycemic control

Authors: Shagun Bindlish

St. Peter’s Health Partners, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Type 2 Diabetes is a progressive disorder characterized by insulin resistance and progressive beta cell failure. Many patients will require insulin therapy to bring glycosylated hemoglobin (HbA1C) levels to nationally standardized goals and thus minimize the risk of both microvascular and macrovascular complications. As the epidemic of type2 diabetes continues to increase (1 in 3 people in US by 2050), it is necessary to develop an accepted blueprint of how insulin should be delivered to this heterogeneous population. Although continuous subcutaneous pump therapy is widely accepted as the standard of care for patients with type 1 diabetes, studies are limited and inconclusive in type 2 diabetes population. Most recently OpT2mise has been completed, a large randomized multi-center trial showing the efficacy of insulin pump therapy in patients already receiving multiple daily injections of insulin. In this presentation, I will highlight this study and others to address the pros and cons of using continuous subcutaneous pump therapy in this challenging population. My goal is to increase awareness among health care providers about the benefit of pump initiation in patients with type 2 diabetes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Shagun Bindlish”